Granted Patent
B2
US 9,931,341 · App. 14/844,041 · Granted Apr 3, 2018
Antagonist of the fibroblast growth factor receptor 3 (FGFR3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of FGFR3
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to the treatment or prevention of skeletal disorders, in particular skeletal diseases, developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FGFR3), in particular by expression of a constitutively activated mutant of FGFR3.
Claims (2)
1. A method for treating a FGFR3-related skeletal disease which comprises the step of administering a therapeutically effective amount of at least one antagonist of the FGFR3 tyrosine kinase receptor of formula:
or a composition comprising such an antagonist, to a subject in need thereof, and treating the FGFR3-related skeletal disease in said subject, wherein the FGFR3-related skeletal disease is achondroplasia.
Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 25, 2022
From: LEGEAI-MALLET, LAURENCE
To: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Reel/Frame 059692/0342 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 25, 2022
From: MUNNICH, ARNOLD; BUSCA, PATRICIA; BARBAULT, FLORENT
To: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM); UNIVERSITE PARIS DESCARTES; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS); ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS; UNIVERSITÉ PARIS DIDEROT - PARIS 7; IMAGINE
Reel/Frame 059692/0913 →
CHANGE OF NAME
Recorded Mar 25, 2022
From: UNIVERSITÉ DE PARIS
To: UNIVERSITÉ PARIS CITÉ
Reel/Frame 059504/0225 →
MERGER
Recorded Jul 22, 2021
From: UNIVERSITE DE PARIS DESCARTES; UNIVERSITE PARIS DIDEROT - PARIS 7
To: UNIVERSITE DE PARIS
Reel/Frame 056947/0567 →